FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that the compensation committee of the board of directors of the Company approved, on September 13, 2021, an equity award to Gregory Reid, the Company’s new VP of Program Development, as a material inducement to Mr. Reid entering into employment with PDS Biotech.

By A Silva